![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 08, 2018 1:28:19 PM
I would like to know more about the FOXP3 densities and proximities to CD8 observed. In case you haven't noticed, I am a firm believer that CTLA-4 on the FOXP3 Tregs are preventing T cell activation.
Would TAVO be more successful if it could be expressed more productively in the TME or TDL? Is tissue heterogeneity preventing adequate expression of IL-12? Would improvements to the plasmid construct lead to better expression, thus improvements in NK cell activation/expansion and FLT3L production? If so, then a program solely focused on improving IL-12 expression would make complete sense.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM